Market Insights Health Pharmaceuticals Vaccines

Other Vaccines - Sudan

Sudan

The Other Vaccines market in Sudan is expected to achieve a revenue of US$2.78m by 2024.
It is projected to display an annual growth rate (CAGR 2024-2029) of 8.55%, leading to a market volume of US$4.19m by 2029.
When compared globally, United States is anticipated to generate the highest revenue of US$24,730.00m in 2024.
Sudan is experiencing an increasing demand for other vaccines due to the government's efforts to improve public health.

Key regions: Australia, Brazil, United Kingdom, Europe, Canada

Market

Region

Region comparison

Currency

Analyst Opinion

The Other Vaccines market in Sudan has been experiencing significant growth in recent years.

Customer preferences: Sudanese customers are increasingly interested in preventative healthcare measures, including vaccinations. This is driven by a growing awareness of the importance of maintaining good health and preventing the spread of infectious diseases.

Trends in the market: The Other Vaccines market in Sudan has seen a surge in demand due to the COVID-19 pandemic. In addition, there has been an increase in demand for vaccines that protect against other infectious diseases, such as measles and polio. This is due to a growing awareness of the importance of vaccination in preventing the spread of disease.

Local special circumstances: Sudan has a large population, with a high birth rate and a significant number of young people. This has led to a growing demand for vaccines to protect against childhood diseases. In addition, Sudan has a high incidence of infectious diseases, including malaria and tuberculosis, which has led to an increased demand for vaccines to protect against these diseases.

Underlying macroeconomic factors: Sudan has a developing economy, with a significant proportion of the population living in poverty. As a result, there is a limited capacity to pay for healthcare services, including vaccinations. However, the government has been investing in healthcare infrastructure and services, which has helped to increase access to vaccines. In addition, there has been growing international support for healthcare initiatives in Sudan, which has helped to increase access to vaccines.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.